id: NEW:aud_medication_treatment_availability_to_alcohol_use_disorder
name: AUD Medication Treatment Availability (Disulfiram, Naltrexone, Acamprosate) â†’ Alcohol Use Disorder
from_node:
  node_id: NEW:aud_medication_treatment_availability
  node_name: AUD Medication Treatment Availability (Disulfiram, Naltrexone, Acamprosate)
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: FDA-approved medications (disulfiram, naltrexone, acamprosate) are available but underutilized
  in healthcare systems'
- 'Step 2: Provider barriers including stigma, lack of knowledge, and lack of professional support limit
  prescribing'
- 'Step 3: Shortage of willing providers creates treatment access gaps'
- 'Step 4: When medications are prescribed, they reduce alcohol craving, block rewarding effects, or create
  aversive reactions'
- 'Step 5: Reduced medication access perpetuates AUD prevalence and severity'
evidence:
  quality_rating: B
  n_studies: 3
  primary_citation: Julie Worley 2021. "Review of Evidence-Based Strategies to Treat Alcohol Use Disorder.."
    https://doi.org/10.3928/02793695-20211110-01
  supporting_citations:
  - Additional citations require full-text access - abstract references FDA-approved medications for AUD
    treatment
  - Evidence base for disulfiram, naltrexone, and acamprosate efficacy referenced
  - Literature on provider barriers to AUD treatment referenced
  doi: 10.3928/02793695-20211110-01
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: FDA-approved medications for AUD (disulfiram, naltrexone, acamprosate) are effective but
  severely underutilized due to systemic healthcare barriers including provider stigma, knowledge gaps,
  lack of professional support, and shortage of willing providers. This represents a structural failure
  in healthcare delivery that perpetuates AUD burden.
spatial_variation:
  varies_by_geography: true
  variation_notes: Provider availability and willingness to prescribe AUD medications likely varies by
    region, healthcare system, and practice setting
moderators:
- name: provider_stigma
  direction: weakens
  strength: strong
  description: Provider stigma toward patients with AUD reduces likelihood of offering evidence-based
    pharmacological treatments
- name: provider_knowledge
  direction: strengthens
  strength: moderate
  description: Greater provider knowledge of AUD medications increases prescribing rates
- name: professional_support_systems
  direction: strengthens
  strength: moderate
  description: Presence of professional support and training increases provider willingness to treat AUD
structural_competency:
  equity_implications: This mechanism highlights how healthcare system failures - not individual patient
    factors - drive AUD treatment gaps. Provider stigma reflects broader societal stigma institutionalized
    in medical practice. Shortage of willing providers is a workforce and training system issue. The focus
    on underutilization shifts blame from patients to structural barriers in healthcare delivery.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.252974'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
